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Abstract
Background: Glaucoma is a leading cause of blindness worldwide. Nonetheless, the mechanism of its pathogenesis has not
been well-elucidated, particularly at the molecular level, because of insufficient availability of experimental genetic animal
models.
Methodology/Principal Findings: Here we demonstrate that deficiency of Vav2 and Vav3, guanine nucleotides exchange
factors for Rho guanosine triphosphatases, leads to an ocular phenotype similar to human glaucoma. Vav2/Vav3-deficient
mice, and to a lesser degree Vav2-deficient mice, show early onset of iridocorneal angle changes and elevated intraocular
pressure, with subsequent selective loss of retinal ganglion cells and optic nerve head cupping, which are the hallmarks of
glaucoma. The expression of Vav2 and Vav3 tissues was demonstrated in the iridocorneal angle and retina in both mouse
and human eyes. In addition, a genome-wide association study screening glaucoma susceptibility loci using single
nucleotide polymorphisms analysis identified VAV2 and VAV3 as candidates for associated genes in Japanese open-angle
glaucoma patients.
Conclusions/Significance: Vav2/Vav3-deficient mice should serve not only as a useful murine model of spontaneous
glaucoma, but may also provide a valuable tool in understanding of the pathogenesis of glaucoma in humans, particularly
the determinants of altered aqueous outflow and subsequent elevated intraocular pressure.
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Introduction
The critical importance of elevated intraocular pressure (IOP) in
the pathogenesis of glaucomatous optic neuropathy is widely
recognized [1,2]. While compromise of aqueous humor outflow is
the key determinant of elevation in IOP [3,4], the molecular
mechanisms underlying changes in the outflow pathway that lead
to elevated IOP remain to be elucidated. For this reason, mouse
genetic knockout models of spontaneous glaucoma are highly
sought after.
The Vav proteins are the best-characterized family of guanine
nucleotide exchange factors (GEFs) that activates Rho guanosine
triphosphatases (GTPases) in a phosphorylation-dependent man-
ner [5]. Rho GTPases control cell behavior via regulating the
specific filamentous actin structures involved in migration,
adhesion, and morphogenesis, by acting as binary switches cycling
between an inactive (GDP-bound) and active (GTP-bound) state
[6]. The three mammalian Vav proteins, Vav1, Vav2, and Vav3,
share a Dbl homology domain for their enzymatic activity as GEFs
and contain a common structural array characteristic of proteins
involved in signal transduction. Regardless of the structural
similarity, Vav proteins differ in their tissue distribution. Vav1 is
expressed specifically in lymphoid lineage cells, whereas Vav2 and
Vav3 are more widely expressed [5,7]. Genetic approaches using
knockout mice have provided valuable information on the func-
tion of Vav proteins in vivo. Vav proteins are crucial for the
development and function of hematopoietic lineage cells such
as lymphocytes, neutrophils, natural killer cells, and osteoclasts
[8–16]. Individual Vav proteins exhibit both redundant and
specialized functions. Despite the wide distribution of Vav2 and
Vav3 proteins in mouse tissues, little is known about their specific
function in non-hematopoietic cells.
While trying to better elucidate the functions of Vav2 and Vav3
in non-hematopoietic cells, we discovered that Vav2/Vav3-
deficient mice have a significant ocular phenotype. Specifically,
we show that Vav2/Vav3-deficient mice have elevated IOP,
which eventually manifests as buphthalmos. Loss of Vav2 and
Vav3 expression is associated with changes in the iridocorneal
angle, with eventual chronic angle closure. The elevation of
IOP in Vav2/Vav3-deficient mice is accompanied by an optic
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9050neuropathy characterized by selective loss of retinal ganglion cells
(RGCs) and optic nerve head (ONH) excavation and is therefore
consistent with glaucoma. In addition, both VAV2 and VAV3 are
shown to be susceptibility loci by single nucleotide polymorphisms
(SNPs) study of Japanese primary open-angle glaucoma patients.
Results
Vav2/Vav3-Deficient Mice Develop Buphthalmos
Eyes of Vav2/Vav3-deficient (Vav2
2/2Vav3
2/2) mice were
noted to develop buphthalmos starting between 6 and 12 weeks of
age (Figure 1). This enlargement was typically seen unilaterally at
first, with frequent bilateral involvement over the next 1–2
months, and continued enlargement until the mice were 6-months
old. Eventually, some of the eyes, became atrophic and phthisical
in appearance (Figure 1A). In order to confirm our initial
observations, we measured the corneal diameters and weights of
Vav2
2/2Vav3
2/2 mice eyes and compared them with age-
matched wild-type mice eyes (Figure 1B). The examination
clearly showed our observations were relevant. We observed 200
Vav2
2/2Vav3
2/2 mice at 6 months of age and almost 75% of
them showed the enlarged eyes (Figure 1C). In addition,
histological study indicated that there were no abnormal findings
in the tissues both around the enlarged eyes such as inflammation,
tumor, or hyperplasia, and in the thyroid of the Vav2
2/2Vav3
2/2
mice (data not shown).
Elevation of Intraocular Pressure of Vav-Deficient Mice
As we observed the development of buphthalmos, we assessed
for elevated IOP in Vav2
2/2Vav3
2/2, Vav2-deficient (Vav2
2/2),
and Vav3-deficient (Vav3
2/2) mice. IOP was measured using a
rodent tonometer (Tonolab) starting at 4 weeks post-natal and
were compared with age-matched wild-type C57BL/6 mice.
Reliable measurement of IOP before 4 weeks of age was not
possible. At 6 weeks of age, Vav2
2/2Vav3
2/2 mice first showed
increased IOP (18.263.1 vs. 14.062.4 mmHg, p,0.05), with
further increases out to 10 weeks of age (22.567.4 vs.
14.664.2 mmHg, p,0.01) (Figure 2A). IOP measurements in
Vav2
2/2Vav3
2/2 mice ranged from 11–40 mmHg between 7
weeks and 16 weeks of age. There was a statistically significant
difference in IOP between the Vav2
2/2Vav3
2/2 and wild-type
mice at all time points demonstrated. The phenotype of littermate
wild type mice was identical to that of the ‘‘inbred’’ C57BL/6
strain (Figure S1).
In Vav2
2/2 mice, elevated IOP was first detected at 7 weeks of
age. The IOP for Vav2
2/2 mice was found to be increased at 8
weeks of age compared to wild-type mice (15.563.7 vs.
14.064.2 mmHg, p,0.05)(Figure 2B). The IOP of Vav2
2/2 mice
showed further increases at 10 weeks of age (18.163.7 vs.
14.664.2 mmHg, p,0.01) and remained significantly higher at
12 weeks. In contrast, the IOP of Vav3
2/2 mice did not differ
significantly from wild-type mice between 8 and 12 weeks
(Figure 2C). The phenotype of littermate wild type mice was
identical to that of inbred strain‘‘C57BL/6’’. We also demonstrated
that the phenotype of Vav2 and Vav3 heterozygous littermate mice
(Vav2
+/2, and Vav3
+/2) were same as that of wild type (Figure S1).
Retinal Ganglion Cell Loss and Optic Nerve Head
Changes in Vav2/Vav3-Deficient Mice
We next examined whether Vav2/Vav3-deficient (Vav2
2/2
Vav3
2/2) mice showed changes in the retinal ganglion cell
(RGC) layer and optic nerve head (ONH). At 3 weeks of age,
Vav2
2/2Vav3
2/2 mice did not show any histological difference in
the ONH or the number of RGCs compared to that of age-
matched wild-type mice (Figure 3A). At 10 weeks of age, following
several weeks of IOP elevation, early signs of ONH cupping and
cell body loss in the RGC layer were apparent in Vav2
2/2Vav3
2/2
mice (Figure 3B). At 15 and 30 weeks of age, Vav2
2/2Vav3
2/2
mice showed further evidence of ONH cupping and RGC loss in
the context of an otherwise normal retinal architecture. These
findings are consistent with a selective loss of RGCs with
corresponding changes in the ONH, which are the hallmarks of
glaucoma.
Iridocorneal Angle Histopathology in Vav-Deficient Mice
As histopathological examination of globes from mice with
buphthalmos frequently demonstrated angle closure, we compared
Figure 1. Vav2/Vav3-deficient mice develop buphthalmos. Eyes
of Vav2/Vav3-deficient (Vav2
2/2Vav3
2/2) mice develop buphthalmos
between 6 and 12 weeks of age. A. Left photo: Representative photo of
unilateral enlarged eye in 10-week-old Vav2
2/2Vav3
2/2 mice. Centre
photo: Representative photo of bilateral enlarged eyes in 16-week-old
Vav2
2/2Vav3
2/2 mice. Right photo: Representative photo of enlarged
eye becoming atrophic in 8-week-old Vav2
2/2Vav3
2/2 mice. B.
Comparison of eye sizes. Left panel: Representative eye of 10-week-
old wild-type (WT) mice as a control (n=20). Cornea diameter is
2.960.1 mm. Weight is 15.861.1 mg. Centre panel: Representative first-
recognized enlarged eye of Vav2
2/2Vav3
2/2 mice (9- to 10-week-old,
n=20). The cornea diameter is 3.360.1 mm. Weight is 23.764.4 mg.
P,0.001. Right panel: Representative moderately enlarged eye of 12-
week-old Vav2
2/2Vav3
2/2mice (n=20). The cornea diameter is
4.260.4 mm. Weight is 38.064.0 mg. C. Age of onset of enlarged eyes
up to 25 weeks of age in Vav2
2/2Vav3
2/2 mice (n=200). The vertical
axis is a cumulative percentage of Vav2
2/2Vav3
2/2 mice with
enlargement of the eyes.
doi:10.1371/journal.pone.0009050.g001
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(Vav2
2/2Vav3
2/2) mice with wild-type mice at both 7 and 12
weeks of age. Angles were classified as either being completely
open, displaying evidence of partial occlusion of the trabecular
meshwork (TM) as manifest by peripheral anterior synechiae
(PAS), or being completely closed (total occlusion of the trabecular
meshwork)(Figure 4A). Over half of the Vav2/Vav3-deficient mice
already showed evidence of angle closure by 7 weeks of age,
increasing to nearly 80% in 12-week-old mice (Figure 4B).
We also examined the correlation between elevated IOP and
angle changes in 7-week-old Vav2
2/2Vav3
2/2 mice respectively
(n=20) (Figure S2). The mean and standard deviation of IOP in
7-week-old wild-type mice (n=18) were 13.763.12 mmHg
respectively. The 95th percentile of those IOPs using a normal
curve was 18.8 mmHg. So that IOP over 18.8 mmHg was
regarded as elevated IOP. Vav2
2/2Vav3
2/2 mice with elevated
IOP showed evidence of angle closure by histological analysis,
while Vav2
2/2Vav3
2/2 mice with non-elevated IOP displayed
either open angles or evidence of early angle closure (PAS) and
angle closure.
In addition, to characterize the progression of angle changes,
two additional time points were added to this analysis of the
iridocorneal angle 218 days and 4 weeks of age (n=20 each).
While at 18 days of age nearly half of the eyes demonstrated open
angles, a large percentage already showed evidence of PAS
(Figure 4B). By 4 weeks of age, Vav2
2/2Vav3
2/2 mice showed
increasing frequencies of both PAS and angle closure. Taken as a
whole, the data showed a gradual progression from open angles to
PAS formation to closed angle from 18 days to 12 weeks.
The iridocorneal angles of Vav2-deficient (Vav2
2/2) and Vav3-
deficient (Vav3
2/2) mice were examined histologically and graded
in a similar manner. The iridocorneal angles of Vav2
2/2 mice also
demonstrated evidence of progressive angle closure, but to a lesser
extent as compared with Vav2
2/2Vav3
2/2 mice (Figure 4B).
Vav3
2/2 mice had normal appearing open angles without
evidence of PAS formation or angle closure (Figure 4B).
In order to better investigate the status of iridocorneal angles in
Vav2
2/2Vav3
2/2 mice, we stained for myocilin as a marker for
TM cells, as myocilin is strongly expressed in TM cells [17]. We
examined 7-week-old Vav2
2/2Vav3
2/2 mice with non-elevated
IOP who had either open angles or who displayed evidence of
angle closure. As shown in Figure S3, myocilin was not detected in
the iridocorneal angle of Vav2
2/2Vav3
2/2 mice with angle
closure, but was seen in mice with open angles similar to those
of wild-type mice.
Effects of Ocular Hypotensives in Vav2/Vav3 -Deficient
Mice
We next tested the efficacy of ocular hypotensives used for
human glaucoma in Vav2
2/2Vav3
2/2 mice with elevated IOP
(Figure S4). The elevated IOP of 7-week-old Vav2
2/2Vav3
2/2 mice
was dramatically reduced by ocular hypotensives used in humans,
such as latanoprost, a prostaglandin analogue (Figure S4A). We
also tested the IOP-lowering effect in Vav2
2/2Vav3
2/2 mice by
two other ocular hypotensives, dorzolamide and timolol, whose
mechanisms of action differ from that of latanoprost [18–20],
being aqueous suppressants (Figure S4B). Furthermore, we tested
Y-27632, a Rho-associated protein kinase inhibitor, that has been
reported to causea reductioninIOPpresumably byaltering cellular
behaviorofTMcells[21–23].Y-27632showednoeffectoflowering
IOPs against Vav2
2/2Vav3
2/2 mice, while it lowered the IOP
significantly in age-matched wild-type mice (Figure S4C).
Expression of Vav2 and Vav3 in Mouse and Human Eyes
In order to understand the pathogenesis of the Vav2/Vav3-
deficient eye phenotype, we examined the mRNA and protein
expression patterns of Vav2 and Vav3 in the eye (Figure 5).
Quantitative real-time PCR revealed that Vav2 and Vav3 mRNA
are expressed in TM, cornea, retina, lens, iris, and ciliary body in
the mouse eye (Figure 5A). Vav3 mRNA was more abundantly
expressed than that of Vav2 in the TM and the retina. Gene
expression levels of both Vav2 and Vav3 in the eye were
comparable to levels found in immune cells where Vavs play a
critical role [5,7–16]. Next, the Vav2 and Vav3 mRNA
localization in mouse eye was examined by in situ hybridization
(ISH) analysis (Figure 5B). Both Vav2 and Vav3 oligo probes
(antisense), we used here, have been examined the specificities
before and proved to have its specificity. As negative controls for
Figure 2. Elevated intraocular pressure of Vav2
2/2Vav3
2/2 and
Vav2
2/2 mice. The intraocular pressure (IOP) of Vav2/Vav3-deficient
(Vav2
2/2Vav3
2/2),Vav2-deficient(Vav2
2/2),andVav3-deficient(Vav3
2/2)
mice were measured between 10–12 AM. At the indicated ages, twenty
mice were examined, respectively. For the IOP measurement of each
Vav-deficient mouse, IOP of an age-matched wild-type (WT) mouse was
also measured under the same conditions. We confirmed that these
resultswerereproduciblewithfourindependentexaminations.A.IO Psof
Vav2
2/2Vav3
2/2 mice were dramatically elevated at 6 weeks of age. B.
Vav2
2/2 mice also showed elevated IOP from around 8 weeks of age. C.
Vav3
2/2 mice have normal range of IOP at any age. Error bars represent
S.D. *P,0.05, **P,0.01 versus WT mice.
doi:10.1371/journal.pone.0009050.g002
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respectively, which showed no detectable signal (Figure S5). Both
genes expression were widely distributed in the ocular tissues
including the iridocorneal angle, retina, cornea, and sclera. The
co- localization of Vav2 and Vav3 mRNA expression in
iridocorneal angle, such as TM, was confirmed by ISH. Also,
we assessed Vav2 and Vav3 protein expression by immunoblotting
in both mouse and human eyes (Figure 5C). In mouse eyes,
expression of both Vav2 and Vav3 was demonstrated in several
ocular tissues including the iridocorneal angle, retina, cornea, and
sclera. Both Vav2 and Vav3 proteins were also expressed in
human retina and iridocorneal angle. The migrated bands were
absent in the liver extracts of the Vav2
2/2Vav3
2/2 mice. Results
of densitometric ratio (Vav3/Vav2) from normalized protein
loading in each lane revealed that Vav3 was more abundantly
expressed than Vav2 in the iridocorneal angle tissues of both
mouse and human eyes and also in the retina.
Single Nucleotide Polymorphisms in Japanese Primary
Open-Angle Glaucoma Patients
We observed Vav2 and Vav3 proteins expression in the tissues
of human iridocorneal angle and retina. In order to investigate the
Figure 3. Optic nerve head degeneration and decrease in RGCs observed in Vav2
2/2Vav3
2/2 mice with elevated IOP. Light-microscopic
histological examination is conducted to evaluate retinal neuropathy in Vav2/Vav3-deficient (Vav2
2/2Vav3
2/2) mice. A. At the age of 3 weeks, Vav2
2/2
Vav3
2/2 miceexhibitedimpairmentofanglestatus, but noabnormal findings ofOpticnerveheaddegeneration(ONH)orretinalganglioncells(RGCs)in
the retinas. Scale bars, from left to right side: 500 mm, 100 mm, and 50 mm. B. After elevation of IOP, compared to control wild-type (WT) mice in the
upper panel, ONH in 10-, 15-, and 30-week-old Vav2
2/2Vav3
2/2 mice present so-called capping (shown in c) and thin retinal neural layers (indicated by
arrows in the photos). In those retinas, RGCs are decreased. Scale bars, from left to right side: 500 mm, 100 mm, and 50 mm. Sections are representative
from 6–12 samples.
doi:10.1371/journal.pone.0009050.g003
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patients, we carried out a genome-wide association study using the
Affymetrix GeneChip Human Mapping 500 K Array Set. We
examined Japanese primary open–angle glaucoma (POAG) cases
and age-matched non-glaucoma controls. Both VAV2 and VAV3
loci in Japanese POAG patients showed SNPs against the non-
glaucoma controls for dbSNPs rs2156323 and rs2801219,
respectively. We reported the most extreme (Table 1). Both were
intronic SNPs, SNP rs2156323 lying in intron3 of VAV2 and SNP
rs2801219 lying in intron1 of VAV3. VAV2 SNP rs2156323 in
particular indicated significant association with Japanese POAG,
including a 5.65 heterozygote odds ratio (95% confidence interval
(CI): 1.99–16.0), 4.34 heterozygote relative risk (95% CI: 1.72–
10.44) and 4.38610
24 genotypic P value with respect to risk allele
A.
Judging from alleric P-values distribution for detecting VAV2
ranking and genotypic P- values distribution for VAV3 ranking, we
observed that VAV2 and VAV3 showed high scores (2log10(P))
among approximately 380,000 SNPs analyzed in this study
(Figure 6). On the contrary, VAV1 showed no association with
the POAG. These data strongly suggest that VAV2 and VAV3
genes are susceptibility loci in Japanese POAG.
Figure 4. Characterization of progressive iridocorneal angle closures in Vav2
2/2Vav3
2/2 and Vav2
2/2 mice. The aqueous humor outflow
facility, trabecular meshwork (TM) and Schlemm’s canal (SC) (iridocornial angle) in Vav2/Vav3-deficient (Vav2
2/2Vav3
2/2) mice are evaluated in
histological manner. Vav2-deficient (Vav2
2/2) mice also have the same changes, but of lower severity. A. Representative photos of normal TM and SC
histology of 12-week-old wild-type (WT) mice as a control. Representative photos of normal open angle, peripheral anterior synechiae (PAS) in 12-
week-old Vav2
2/2Vav3
2/2 mice, and angle closure status in 12-week-old Vav2
2/2Vav3
2/2 mice. Sections used here are all representative from 20
samples. Scale bars: left photos, 200 mm; right photos, 100 mm. B. Changes of angle status appear at the early ages. We classify angle status of Vav2
2/2
Vav3
2/2, Vav2
2/2, and Vav3
2/2mice into open angle, PAS, and angle closure by histological evaluation. We find the changes of angle status at the early
ages, such as in 18-day-old Vav2
2/2Vav3
2/2 mice (n=20) andin 4-week-old of Vav2
2/2Vav3
2/2 mice (n=20). We took four (Vav2
2/2Vav3
2/2) andthree
(Vav2
2/2, Vav3
2/2) different age groups, with 20 mice examined, respectively.
doi:10.1371/journal.pone.0009050.g004
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To our knowledge, this is the first report of a spontaneous
glaucoma phenotype in Vav2 (Vav2
2/2) or Vav2/Vav3-deficient
(Vav2
2/2Vav3
2/2) mice. Vav2/Vav3-deficiency is associated with
progressive iridocorneal angle changes and elevation of IOP in
mice. Subsequent selective loss of RGCs and progressive ONH
cupping are associated with this elevated IOP, as has previously
been demonstrated in other rodent models of glaucoma [24]. The
finding that Vav2-deficiency alone results in a glaucoma
phenotype suggests that the absence of Vav2 plays a critical role
in the development of this phenotype. Despite our finding that
Vav3-deficiency did not result in either iridocorneal angle changes
or elevated IOP, the more severe glaucomatous phenotype
demonstrated in Vav2
2/2Vav3
2/2 mice as compared with
Vav2
2/2 mice is consistent with an additive effect.
A number of induced glaucoma models have been established in
rats and mice [24]. Each model has advantages and disadvantages,
related to factors such as the ease of inducing elevated IOP, the
magnitude, duration and variability of elevated IOP, and
secondary effects on the eye. Due to the ease of genetic
manipulation, mouse models are becoming increasingly popular
over those in rats. Despite the lack of a lamina cribosa as found in
human eyes, the mouse is a good genetic model to study the
pathogenesis of human glaucoma as aqueous physiology and
anterior segment anatomy are similar to that found in humans
[25].
Other spontaneous models of glaucoma have been described in
mice, most notably in DBA/2J mice. The pigmentary glaucoma
phenotype demonstrated in the DBA/2J mice has been extensively
studied at genetic, clinical, morphological and pathological levels
[26–29]. A limitation of this model is that the elevated IOP
phenotype is not primary but secondary due to the systemic
pigment dispersion syndrome with the associated mutations in the
Gpnmb and Tyrp1 loci [26–30]. In these mice, recessive mutations
in these 2 genes are associated with iris degeneration characterized
by iris stromal atrophy and pigment dispersion with subsequent
reduced outflow facility secondary to pigment and cell debris.
Therefore, it is difficult to tie-in the identified mutations to the
pathogenesis of any primary form of human glaucoma.
The Vav2/Vav3-deficient mouse has several characteristics
which make it particularly useful as an animal glaucoma model.
The elevated IOP occurs spontaneously in these genetically
manipulated mice and does not require the ocular manipulation
necessary in induced models. The frequency of the ocular
phenotype is high and onset occurs at a relatively young age. In
addition, ocular hypotensives commonly used to treat human
glaucoma show efficacy in lowering IOP in this model. The most
significant advantage of this mouse glaucoma model is that the
deleted genes, Vav2 and Vav3, are well-focused targets that have
been studied over 20 years providing a useful starting point for
further investigation of the potential molecular mechanisms
underlying this phenotype.
Several aspects of this model of spontaneous glaucoma will
require further study and clarification, although we speculated
from our histological results and the correlation between elevated
IOP and angle status changes that anatomic angle closure is the
possible mechanism for elevated IOP in this model. While
progressive angle closure may be the etiology prior to elevated
IOP in mice lacking Vav2 and Vav3 function, it may alternatively
be a subsequent change related to other alterations in angle
structures which might also affect aqueous humor outflow. In
addition, since the expression of Vav2 and Vav3 was detected in
ocular tissues other than those comprising the iridocorneal angle, it
will be necessary in future studies to consider how their deficiency
in these tissues might have potentially contributed to the
spontaneous glaucoma phenotype in any way.
While so far there are several reports of glaucoma associated
candidate genes based on the single nucleotide polymorphisms
(SNPs) study in the Japanese population [31–36], our data first
suggest that VAV2 and VAV3 are susceptibility loci in Japanese
primary open–angle glaucoma (POAG) cases. In addition, so far we
could not find the report of non-Japanese glaucoma association case
study that demonstrated VAV2 and/or VAV3 as candidate gene loci
for glaucoma [37–43]. They demonstrated glaucoma associated
candidate genes study with SNPs analysis focusing on the other
specific target genes, although we are interested in the VAV2 and/or
VAV3 glaucoma association study using the different populations.
This work would be important investigation to be done.
Although our current findings do not address the molecular
mechanisms underlying glaucoma phenotypes, it is interesting to
consider possible mechanisms based on what is currently known
about Vav protein function. The TM has been regarded as a key
determinant of IOP and has been implicated as the major site of
Table 1. Vav2, Vav3, Vav1 association study for POAG using the Affymetrix GeneChip.
Gene VAV2 VAV3 VAV1
SNP ID rs2156323 rs2801219 rs2617815
Chromosome Location 9q34.1 1p13.3 19p13.2
Position 133750375 108214454 6746147
Genotypic P value 4.38610
24 5.42610
24 4.41610
22
Allele AG AC AG
Risk allele A C G
Minor allele A C G
Heterozygote odds ratio (95%CI) 5.65 (1.99–16.0) 2.03 (1.01–4.09) 1.04 (0.52–2.08)
Heterozygote relative risk (95%CI) 4.34 (1.72–10.44) 1.31 (1.00–1.75) 1.01 (0.82–1.23)
Homozygote odds ratio Not Available Not Available Not Available
Exon Intron VAV2 Intron3 VAV3 Intron1 VAV1 Intron1
SNP type iSNP*1 iSNP iSNP
*1: intronic S.
doi:10.1371/journal.pone.0009050.t001
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PLoS ONE | www.plosone.org 6 February 2010 | Volume 5 | Issue 2 | e9050Figure 5. Vav2 and Vav3 expression in mouse and human eyes. A. Quantitative real time PCR analysis is performed for Vav2 and Vav3 mRNA
expression study. The vertical axis is the copy number of Vav2 or Vav3 mRNA when that of mGAPDH is taken as 1. The assay method is absolute
quantification (standard curve). a. Both Vav2 and Vav3 mRNA are expressed in all tissues of the murine eyes including the trabecular meshwork (TM),
cornea, sclera, and retina. b. Vav2 and Vav3 mRNA expression level of murine immune cells. The levels of Vav2 and Vav3 expression in eye tissues are
the same as those of the immune cells where Vav2 and Vav3 play the critical role. B. a. In situ hybridization analysis of emulsion-dipped sections
display the distribution of Vav2 and Vav3 mRNA in the anterior chamber. The localization of Vav2 and Vav3 mRNA in trabecular meshwork(TM), ciliary
body (CB), cornia(CO), iris(Ir), sclera (Scl) and retina(Re) by in situ hybridization. b. Vav2 and Vav3 mRNA expression are both detected in iridocorneal
angle, such as TM (indicated by arrows in the photos). Scale bars, 50 mm. C. Expression of Vav2 and Vav3 proteins in mouse (a) and human (b) eyes.
Vav2 and Vav3 proteins were detected in mouse or human ocular extracts (from two independent postmortem eye globe samples; at death age of 58
(1) and 87 (2)) by western blotting. Densitometric ratios (Vav3/Vav2) were shown under the blotting panels. mICA: mouse iridocorneal angle tissues,
mR: mouse retina, mR’: 3-fold increased loading mouse retina, mC: mouse cornea, mS: mouse sclera, mLiv: normal mouse liver(positive control), KO:
Vav2/Vav3-deficient mouse as a negative control, hICA: human iridocorneal angle tissue,hR1: human retina 1, hR1’: human retina1’ (3-fold loading).
doi:10.1371/journal.pone.0009050.g005
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glaucoma [44,45]. Recent findings indicate that signals emanating
from integrins, key regulators of the actin cytoskeleton in trabecular
meshwork cells, may be involved in control of outflow facility and
RhoGTPases would be important downstreameffectors of integrin-
mediated actin cytoskeletal dynamics [4,46–48]. Considering the
Vavs function as GEF, dysregulation of Rho is one possible
mechanism by which pathology in the iridocorneal angle might
result and is one that deserves further study.
In summary, we had demonstrated that Vav2/Vav3-deicient mice
develop a spontaneous glaucoma phenotype. In addition, our data first
suggest that VAV2 and VAV3 are susceptibility loci in Japanese primary
open-angle glaucoma (POAG) cases. We believe that Vav2/Vav3-
deficient mice will serve not only as a useful murine model of
spontaneous glaucoma, but may also provide a valuable tool in
understanding of the pathogenesis of glaucoma in humans, particularly
the determinants of altered aqueous outflow and elevated IOP.
Materials and Methods
Mice
Vav3
2/2, Vav2
2/2 and Vav2
2/2Vav3
2/2 mice were described
previously [15]. Mice were backcrossed at least 9 times with
C57BL/6 mice (Clea Japan, Tokyo, Japan) to have the C57BL/6
background. All mice used in these experiments were bred and
maintained in the SPF Facility of Hokkaido University Graduate
School of Medicine in a 12-hour light-dark cycle. All mice
experiments were approved by the Animal Ethics Committee of
Hokkaido University Graduate School of Medicine and were
conducted in accordance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research.
Tissue Preparation and Histology
Eyes were quickly enucleated from each age group of knock-out
mice and C57BL/6 wild-type control mice after deep anesthesia
with pentobarbital sodium solution, then immediately fixed with
solution of 2.5% glutaraldehyde (TAAB, EM Grade) in 10%
formalin neutral buffer-methanol solution deodorized for anterior
chamber study, or fixed with Davidson’ solution for retinal analysis
for 12 hours. Following this, the eyes were embedded in paraffin
and dissected sagittally using a microtome into 5 mm sections.
After deparaffinization and rehydration, the sections were stained
with hematoxylin and eosin (Sigma).
Immunohistochemistry
The eyes were sectioned at 5 mm thickness along the vertical
meridian through the optic nerve head. After deparaffinization and
rehydration, the tissue sections were incubated with blocking solution
containing 1% BSA in PBS for 1 hour. This was followed by 1 hour
incubation with rabbit polyclonal antibody to myocilin at 1:200 in
blocking solution as first antibody for 1 hour at room temperature.
Anti-rabbit IgG conjugated with Alexa 488 (Molecular Probes,
Eugene, OR) at 1:400 in PBS containing 0.1% Tween 20 was used as
secondary antibody for 1 hour at room temperature. The stained
tissues were examined using confocal fluorescence laser microscope
(Radius 2000, Bio-Rad, Hercules, CA). For negative control of the
immunohistochemical staining, the sections were incubated with
blocking solution without primary antibody (data not shown).
Real Time PCR
Each tissue was freshly taken from SPF level C57BL/6 mice and
immediately used for generating RNA by TRIzol reagent
(Invitrogen). Templates for real time PCR were made by Cloned
AMV Reverse Transcriptase (Invitrogen). Probes of mVav2 and
mVav3 were TaqMan probes (Vav2: Mm00437287_m1, Vav3:
Mm00445082_m1) purchased from Applied Biosystems (Foster
city, CA). The standard curves were constructed by mVav2,
mVav3 inserted plasmids, normalized by mGAPDH (Product
Code: 4352339E, Applied Biosystems). All the PCR studies were
performed by Applied Biosystems 7500 Real Time PCR System
following the manufacturer’s recommended procedures. The assay
method was absolute quantification (standard curve).
In Situ Hybridization
The detailed procedure was described as previously [49]. Briefly, to
detect mRNAs for Vav2 and Vav3, specific antisense oligonucleotide
probes were synthesizedas follows:(2275–2319;45mers)59-AGCTG-
GAGACCGGCTTGAGGCC CTGCTGGTGGTTCGCTCCCG-
AGA-39 for Vav2 mRNA (GenBank accession No. NM_009500) and
(2346–2302;45mers)59–GTTGCCTGTTCTATTACCCCTCTG T
CCAGCTGGCTGTTCTGGCTC-39 for Vav3 mRNA (accession
No. NM_020505). Oligonucleotide probes were labeled with [33P]
Figure 6. VAV2 and VAV3 genome-wide SNPs high ranking of P-value scores. Genome-wide ranking orders of P-value indicate that VAV2 and
VAV3 are strongly susceptible genes with Japanese POAG cases. Clinically diagnosed Japanese POAG 100 cases and non-glaucoma age-matched 100
controls are examined for this study. The analysed SNPs number is about 380,000 by the Affymetrix GeneChip 500 K Mapping Array Set. The SNPs
data under the 85% call rate, under 0.001 Hardy-Weinberg equilibrium (HWE), and under 5% minor allele frequencies are excluded. Allelic frequency
x2 test and genotypic frequency x2 test are calculated respectively. The vertical axis is 2log10 (P) and the horizontal axis is SNPs order which showed
high scores from left to right. The Upper graph is alleric P-values distribution of VAV2 analysis and the lower graph is genotypic P-values for VAV3 and
VAV1 study. VAV2 is located at high position in rank and VAV3 also located at high position in rank. VAV1 shows no association for POAG cases here.
doi:10.1371/journal.pone.0009050.g006
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Carlsbad, CA). Under deep pentobarbital anesthesia, the eyeballs were
freshly obtained from Adult C57BL/6J mice. Fresh frozen sections
(20 mm thickness) were cut with a cryostat (CM1900, Leica,
Nussloch,Germany) and mounted on glass slides precoated with 3-
aminopropyltriethoxysilane. Sections were exposed to Nuclear Track
emulsion (NTB-2, Kodak) for 5 weeks. Emulsion-dipped sections were
stained with methyl green pyronine solution. The specificity of the
hybridizing signals was verified by the disappearance of signals when
hybridization was carried out with sense probes.
Western Blotting
Mouse Ocular Tissue Dissection: 8-week male C57BL/6J mice
(Jackson Laboratory, ME) were used for ocular tissue samples. The
animals were euthanized by carbon dioxide inhalation in an
induction chamber. The globes were promptly enucleated after
euthanization and washed in ice-cold PBS. Ocular tissues were
microscopically dissected. Dissection of Postmortem Human Eye
Globes: Human eyes without previous eye diseases including
glaucoma were acquired from a local eye bank (Heartland Lions
Eye Banks; Columbia, MO) within 6 hours post-mortem.
Dissected mouse and postmortem human ocular tissues were
lysed in a tissue extraction buffer (BioChain, CA). The
concentration of protein supernatants was determined by a
protein assay kit (Bio-Rad, CA). Rabbit polyclonal anti-mouse
Vav2 (1:1000) (Santa Cruz Biotechnology, CA), monoclonal anti-
human Vav2 (1:2000) (Cell Signaling Technology, MA), poly-
clonal anti-mouse and anti-human Vav3 (1:3000 for each)
(Millipore, CA) antibodies were used for detection.
Intraocular Pressure (IOP) Measurement
IOP was measured using the TonoLab rebound tonometer for
rodents (Tiolat i-care, Finland) according to the manufacturer’s
recommended procedures. All IOP measurements were performed
between 10 AM and noon in conscious condition. Mice were
gently restrained first by hand and placed on a soft towel bed on
the desk and usually appeared calm and comfortable. These data
were confirmed to be reproducible by three additional different
independent studies (n=20).
Evaluation of Eye Drop Medications for High Intra-Ocular
Pressure of Vav2Vav3-Deficient Mice
Vav2
2/2Vav3
2/2 mice were housed in SPF barrier facility in
standard lighting conditions (12-hour light-dark cycle). The 7–9
week after birth mice were used for the experiment. Four
independent experiments were carried out to confirm the results
reproducible.
Preparation and Application of Ophthalmic Solution
Latanoprost was purchased from Cayman Chemical Co. (Ann
Arbor, MI) and dissolved in its vehicle solution (0.02% benzalk-
onium chloride, 0.5% monosodium phosphate monohydrate,
0.6% disodium hydrogen phosphate dihydrate and 0.4% sodium
chloride). With a micropipette, 3 ml of PG analogue (latanoprost;
prostaglandin F2a) solution or vehicle was randomly applied to the
eyes of Vav2
2/2Vav3
2/2 mice. Before administration, IOP was
measured with the tonometer from 10–12 AM and then the PG
analogue 0.005% 3 ml or vehicle solution was applied in a masked
manner. Evaluation of IOP-lowering effect was performed by
measuring the IOP with the tonometer at 3 hours after drug
instillation also in a masked manner. Furthermore, two different
mechanistic medications, 3 ml of timolol maleate (0.5%, Merck,
Whitehouse Station, NJ) or 3 ml of dorzolamide hydrochloride
(1%, Trusopt; Merck), was also tested, respectively, after
measuring the IOP under the same conditions as those of the
Latanoprost application. Evaluation of IOP-lowering effects was
performed by measuring the IOP with tonometer at 2 hours after
drug instillation under blinded test protocols. Y-27632 was
purchased from Carbiochem (La Jolla, CA) and dissolved in its
vehicle solution (phosphate buffered saline). Y-27632 (1 mM) or
vehicle solution was administered to the central cornea as a 3 ml
drop by pipetting in a masked manner. Evaluation of IOP-
lowering effect was performed by measuring the IOP with the
tonometer at 1 hour after drug instillation.
Statistical Analysis of IOPs
Data are reported as means 6 S.D. Two-tailed Student’s t-test
was used to compare between two groups of results. Differences
between any two groups were regarded as significant when
P,0.01(**) or P,0.05 (*).
Disease Associated Genome-Wide Analysis
One hundred clinically-diagnosed cases (male 46; female 54)
with primary open-angle glaucoma over 30 years of age (mean
age, 71.60 years; SD, 9.33 years) and non-glaucoma age-matched
controls (mean age, 66.71 years; SD, 12.00 years) in a Japanese
population were examined for this study. Informed consent was
obtained from all participants, and the procedures used conformed
to the tenets of the Declaration of Helsinki. Genomic DNAs were
isolated from the peripheral blood of the POAG cases and age-
matched controls for genotyping analysis. Genotyping was
performed using the Affymetrix GeneChip Human Mapping
500 K Array Set (Affymetrix Services Laboratory, California). We
omitted the SNP data under an 85% call rate, under 0.001 Hardy-
Weinberg equilibrium (HWE), and under 5% minor allele
frequency. Data analysis was performed using the LaboServer
System (World Fusion, Tokyo Japan). An allelic frequency x
2 test
and genotypic frequency x
2 test were calculated, respectively with
respect to risk allele. The Odds ratio was calculated in three
manners such as per allele odds ratio, heterozygote odds ratio, and
homozygote odds ratio. Relative risk was also calculated, the same
as for the odds ratio. The most significant SNPs were chosen in
this report to evaluate the association of VAV2, VAV3, and VAV1 in
the cases.
Supporting Information
Figure S1 The comparison of intraocular pressures in age
matched wild-type inbred C57BL/6 mice, wild-type littermate
controls, and Vav2 and Vav3 heterozygous mice (Vav2
+/2, and
Vav3
+/2). Intraocular pressures (IOPs) were measured using the
TonoLab rebound tonometer for rodents from 6-week to 12-week,
as described in the Methods. The phenotype of littermate wild-
type mice was identical to that of the ‘‘inbred’’ C57BL/6 strain.
The phenotype of Vav2 and Vav3 heterozygous mice were similar
to that of wild-type. n=20.
Found at: doi:10.1371/journal.pone.0009050.s001 (0.45 MB TIF)
Figure S2 The correlation between elevated IOP and angle
changes in Vav2/Vav3-deficient mice. The IOP was measured in
7-week-old Vav2/Vav3-deficient (Vav2
2/2Vav3
2/2) mice
(n=20), followed by examination of the angle status by histology.
While Vav2
2/2Vav3
2/2 mice with elevated IOP displayed
histological evidence of angle closure, mice without elevated IOP
showed either normal open angles or evidence of angle changes,
angle closure or peripheral anterior synechiae. The mean and
standard deviation of IOP in wild-type mice at 7-week-old (n=18)
were 13.763.12 mmHg, respectively. The 95th percentile of those
Glaucoma in Vav-Deficient Mice
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18.8 mmHg was regarded here as elevated IOP.
Found at: doi:10.1371/journal.pone.0009050.s002 (0.57 MB TIF)
Figure S3 Anti-myocilin staining of trabecular meshwork in
Vav2/Vav3-deficient mice. Immunohistochemical staining of
trabecular meshwork with anti-myocilin antibody in representative
iridocorneal angle sections of age-matched wild-type and Vav2/
Vav3-deficient (Vav2
2/2Vav3
2/2) 7-week-old mice with normal
IOP, with either evidence of angle closure, or normal open angles
similar to wild type mice. Myocilin (green-labeled), which is
strongly expressed in TM cells, was regarded as a marker for TM
cells. In Vav2
2/2Vav3
2/2 mice with angle closure, myocilin was
not detected in the iridocorneal angle (indicated by arrows).
Conversely, it was detected in sections from mice with normal
open angles, similar to those in wild type mice. Blue fluorescence is
DAPI counter staining. Scale bars, 20 um.
Found at: doi:10.1371/journal.pone.0009050.s003 (2.19 MB TIF)
Figure S4 Effects of ocular hypotensives in Vav2/Vav3-deficient
mice. A. Ocular hypotensives used for human glaucoma,
latanoprost, a prostaglandin analogue was tested in 7-week-old
Vav2/Vav3-deficient (Vav2
2/2Vav3
2/2) mice with elevated IOP
(n=20). The IOP was measured 3 hours before and after topical
application of 3 ml of 0.01% latanoprost in a masked manner.
Vehicle was used as a control. Latanoprost lowered the IOP
significantly in Vav2
2/2Vav3
2/2 mice (26.365.0 mmHg versus
15.865.1 mmHg; n=20), while the IOP was not altered by the
vehicle alone. The latanoprost-induced reduction of IOP in
Vav2
2/2Vav3
2/2mice was statistically significant (**P,0.01,
n=20). The data shown are representative of three independent
experiments performed. Error bars represent S.D. **P,0.01
versus vehicle-treated Vav2
2/2Vav3
2/2 mice. B. Using three
different drugs for lowering IOP, we compared the effects by
percentages of elevated IOP reduction. These data are represen-
tative from three independent experiments, respectively (n=20).
Error bars represent S.D. **P,0.01 versus vehicle-treated Vav2
2/2
Vav3
2/2 mice.C.Rho-associated proteinkinaseInhibitor,Y-27632
was tested for lowering IOP on Vav2
2/2Vav3
2/2 mice (n=20).
Y27632 administration has no effect against Vav2
2/2Vav3
2/2
mice (before, 19.6964.98 mmHg; after, 18.8365.60 mmHg; n=20),
while Y-27632 lowered the IOP significantly in age-matched wild-
type mice (13.5862.27 mmHg versus 12.3161.94 mmHg; n=20.
p,0.05) and the IOP was not altered by the vehicle solution
(13.2561.71 mmHg versus 13.1863.17 mmHg; n=20). These
data are representative from four independent experiments,
respectively. Error bars represent S.D. *P,0.05 versus vehicle-
treated WT mice.
Found at: doi:10.1371/journal.pone.0009050.s004 (0.41 MB TIF)
Figure S5 Sense probe staining for in situ hybridization
experiments in ocular tissues. In situ hybridization with Vav2
and Vav3 sense probes were carried out as negative controls for
the experiments. C57BL/6 mouse ocular tissue sections including
the iridocorneal angle, sclera and cornea were used. With sense
probes, there was no detectable signal around mouse iridocorneal
angle tissues. TM; trabecular meshwork. Scl; sclera.
Found at: doi:10.1371/journal.pone.0009050.s005 (4.14 MB TIF)
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